Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent

Ultragenyx Pharmaceutical (RARE) reports first-quarter 2026 earnings after market close on May 5, 2026, with investors focused on whether the rare disease specialist can demonstrate sustained commercial momentum and narrow its path to profitability. The company has delivered mixed results over the past year, with two earnings beats offset by two significant misses, creating uncertainty about execution consistency. With analysts projecting meaningful improvement in the bottom line over the next two years and the stock trading well below its 52-week high, this report will test whether Ultragenyx can validate the bullish thesis that its approved therapies and pipeline progress justify current valuations.

Part 1: Earnings Preview

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing novel products for rare and ultra-rare genetic diseases, with approved therapies including Crysvita (for XLH and TIO), Mepsevii (for MPS VII), and Dojolvi (for LC-FAOD), alongside a robust pipeline targeting additional rare metabolic, neurological, and genetic conditions. The company reports Q1 2026 results after the close on May 5, with analysts expecting a loss of $-1.55 per share on revenue estimates not disclosed in the available data. Most recently, RARE reported Q4 2025 earnings of $-1.29 per share on February 12, 2026.

Compared to the same quarter last year, when the company posted a loss of $-1.57 per share, the current consensus of $-1.55 represents a modest year-over-year improvement of 1.27%, suggesting analysts expect only incremental progress in narrowing losses. Three key themes define this earnings story heading into the release:

Commercial Execution and Revenue Growth: Investors will scrutinize sequential and year-over-year growth in product net sales, particularly for flagship therapies Crysvita and Dojolvi, as sustained revenue expansion is critical to demonstrating the company's ability to scale its commercial operations and move toward profitability. Patient population growth, reimbursement dynamics, and market penetration rates will be key metrics.

Pipeline Progress and Regulatory Milestones: With the FDA's recent acceptance of the BLA resubmission for UX111 AAV gene therapy to treat Sanfilippo Syndrome Type A (announced April 2, 2026), investors are watching for updates on clinical trial milestones, regulatory timelines, and potential product launches that could expand the company's addressable market and revenue base in the coming years.

Path to Profitability and Cash Management: With analysts projecting dramatic improvement from a $-4.49 loss per share in 2026 to just $-0.19 in 2027 (a 95.77% improvement), the market is focused on whether management can demonstrate disciplined R&D spending, extend the cash runway, and articulate a credible timeline for reaching breakeven or profitability.

Analyst commentary ahead of the release reflects cautious optimism, with 18 of 22 analysts rating the stock a Strong Buy and a mean price target of $53.35 implying substantial upside from current levels. However, the wide range of estimates—from a high of $-1.06 to a low of $-2.01 per share—underscores uncertainty about near-term execution, while the dramatic spread in 2027 estimates (from $5.66 profit to $-2.57 loss) reveals deep disagreement about the company's ability to achieve its long-term financial inflection point.

Part 2: Historical Earnings Performance

Ultragenyx has delivered inconsistent earnings performance over the past four quarters, with two beats and two misses creating a volatile pattern that has likely contributed to investor uncertainty. In Q1 2025, the company missed estimates by 1.95%, reporting $-1.57 versus the $-1.54 consensus. The following quarter brought a 7.87% beat, with actual results of $-1.17 coming in better than the $-1.27 estimate. However, Q3 2025 saw the most significant disappointment, with a massive 47.15% miss as the company reported $-1.81 against expectations of just $-1.23. Most recently, Q4 2025 brought another miss of 7.50%, with $-1.29 reported versus the $-1.20 estimate.

The pattern reveals no clear trend of consistent improvement or deterioration—instead, RARE's results have been characterized by volatility and unpredictability. The company has beaten estimates in only two of the last four quarters, and when it misses, the magnitude can be substantial, as evidenced by the Q3 2025 result that came in nearly 50% worse than expected. This inconsistency makes it difficult for investors to model the business with confidence and may explain why analyst estimates for the upcoming quarter span such a wide range, from $-1.06 to $-2.01.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Ultragenyx typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around earnings reveals significant volatility, with the stock averaging an absolute move of 5.39% on Day +1 (the first full trading session after results) and an intraday range of 10.64% on that day. The most dramatic reaction came after the May 2025 report, when the stock dropped 9.80% on Day 0 and extended losses to 4.68% on Day +1, reflecting the market's negative response to that quarter's miss. Conversely, the August 2024 report triggered a powerful 14.31% rally on Day +1 despite a modest 1.93% decline on Day 0, demonstrating how positive surprises can generate substantial upside.

The February 2026 report (most recent) saw relatively muted Day 0 action with a 1.59% decline, but Day +1 brought a more substantial 12.68% drop as investors digested the Q4 miss and forward guidance. The Day 0 average absolute move of 2.57% with a 4.62% range suggests modest anticipatory positioning, while the much larger Day +1 move and 10.64% range indicate that the real price discovery happens after results are released. Investors should prepare for potential double-digit percentage swings in either direction based on whether the company beats or misses estimates and, critically, what management says about the path to profitability.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.26% (±$1.80) for the May 15 expiration, which is notably higher than the historical Day 0 average move of 2.57% but lower than the Day +1 average of 5.39%. This suggests options traders are anticipating meaningful volatility but not the extreme 10%+ moves seen in some recent quarters, positioning the expected move roughly in line with typical post-earnings reactions while leaving room for outsized moves if results or guidance significantly surprise.

Part 3: What Analysts Are Saying

Analyst sentiment on Ultragenyx remains decidedly bullish, with 18 of 22 analysts rating the stock a Strong Buy, one rating it a Moderate Buy, and just three assigning Hold ratings. No analysts currently rate RARE a Sell or Strong Sell. The average recommendation of 4.68 on a 5-point scale reflects strong conviction in the stock's upside potential, while the mean price target of $53.35 implies 115% upside from the current price of $24.81. The range of price targets is wide, spanning from $25.00 to $84.00, indicating significant disagreement about the company's ultimate valuation but with even the low-end target roughly in line with current levels.

Sentiment has remained unchanged over the past month, with the same distribution of 18 Strong Buys, 1 Moderate Buy, and 3 Holds as one month ago. This stability suggests analysts are maintaining their bullish stance despite recent earnings volatility and are likely waiting for the upcoming Q1 report to reassess their views. The consensus appears anchored on the belief that Ultragenyx's approved therapies will drive accelerating revenue growth while pipeline progress—particularly the UX111 BLA resubmission—positions the company for meaningful expansion in addressable markets. The dramatic improvement analysts expect in 2027 earnings (from $-4.49 in 2026 to $-0.19 in 2027) underpins the bullish thesis, though the wide range of 2027 estimates ($5.66 to $-2.57) reveals that this optimism is far from unanimous and depends heavily on successful execution across multiple fronts.

Part 4: Technical Picture

Ultragenyx enters earnings with a deteriorating technical picture that has shifted from neutral to bearish over the past month. The Barchart Technical Opinion currently registers a 24% Sell signal, representing a significant weakening from the 40% Sell signal one week ago and the much stronger 64% Sell signal one month ago. While the recent improvement from 64% to 24% suggests some stabilization, the overall signal remains in sell territory, indicating technical headwinds persist.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stabilized after recent weakness, with the stock finding some equilibrium ahead of earnings
• Medium-term (50% Sell): Moderate sell signal indicates the intermediate-term trend remains under pressure, reflecting concerns about the stock's ability to sustain any rallies
• Long-term (50% Sell): Moderate sell signal shows the longer-term trend has deteriorated from earlier strength, with the stock struggling to maintain its position relative to key moving averages

Trend Characteristics: The technical environment is characterized by a Weak trend with the Weakest directional momentum, suggesting the stock lacks conviction in either direction and is vulnerable to sharp moves on earnings news.

The stock is currently trading at $24.81, positioned above its 5-day ($24.60), 10-day ($24.41), 20-day ($24.27), and 50-day ($22.59) moving averages, indicating short-term relative strength. However, the price remains below the critical 200-day moving average of $27.71, confirming the longer-term downtrend remains intact. The fact that RARE is above its 50-day but below its 200-day moving average places it in a transitional zone where the earnings report could determine whether the stock breaks out to challenge longer-term resistance or rolls over back toward recent lows.

Key technical levels to watch include the 50-day moving average at $22.59 as immediate support and the 200-day moving average at $27.71 as the critical resistance level that would need to be reclaimed to signal a meaningful trend reversal. The stock's position above short-term moving averages provides some cushion, but the weak directional momentum and sell signals across multiple timeframes suggest the technical setup is cautionary rather than supportive heading into earnings. A strong beat with positive guidance could catalyze a breakout above the 200-day moving average, while a miss or disappointing outlook could quickly erase recent gains and send the stock back toward the $22-23 support zone.